PGI2 Cancer Research Results

PGI2, Prostacyclin / Prostaglandin I2: Click to Expand ⟱
Source:
Type:

PGI2 - Prostacyclin / Prostaglandin I2

Abbreviation: PGI2

Type: Prostaglandin / eicosanoid lipid mediator

Function: Short-lived prostaglandin produced primarily by vascular endothelial cells from arachidonic acid through cyclooxygenase and prostacyclin synthase. PGI2 activates the prostacyclin receptor (IP/PTGIR), increases cAMP, promotes vasodilation, inhibits platelet aggregation, and regulates vascular, inflammatory, and immune signaling.

Cancer: ↓ Frequently reduced or functionally suppressed in cancer. PGI2 signaling can inhibit tumor growth, platelet-mediated metastatic dissemination, inflammation, and tumor progression. Increased prostacyclin synthesis or signaling has demonstrated tumor-suppressive and anti-metastatic effects in several experimental cancer models.

Alzheimer's Disease: ↑ Increased or prolonged PGI2 signaling may contribute to disease pathology. Experimental PGI2 overexpression has been shown to increase soluble Aβ42, accelerate amyloid accumulation, disrupt cerebral microvascular architecture, and worsen cognitive impairment in amyloidosis models.
Scientific Papers found: Click to Expand⟱
7324- GSE,    A Pilot Study of a Grape Seed Procyanidin Extract for Lung Cancer Chemoprevention
- Trial, Lung, NA
BioAv↑, a standardized GSE complexed with soy phospholipids to enhance bio-availability, in heavy active and former smokers
toxicity↝, In general, three months of LP, reaching the highest dose per study protocol was well tolerated and no dosing adjustment was necessary.
Ki-67↓, significantly decreased bronchial Ki-67 LI by an average of 55%
miR-106b↓, with concomitant decreases in serum microRNA (miR) -19a, -19b and -106b
chemoPv↑, findings nonetheless support the continued clinical translation of GSE as an anti-neoplastic and chemopreventive agent against lung cancer.
Dose↝, 1 capsule (cap), 450 mg/cap/day for week one, 2 caps/day for week 2, 3 caps/day for week 3, then 4 cap/day for the rest of the treatment duration as tolerated.
miR-19b↓, Figure 5 downregulating oncomirs miR19-a, -19b, -106b a
PTEN↑, increases in tumor suppressors PTEN, IGF2R and decrease in activated p-Akt by miR-19a/b
IGF-2R↑,
p‑Akt↓,
PGE2↓, decreases in PGE2 and PGI2 due to COX-2 inhibition
PGI2↓,
COX2/PTGS2↓,
Apoptosis↑, GSE increases apoptosis, decreases cell proliferation, decreases inflammation,
TumCP↓,
Inflam↓,
cardioP↑, favorable side effect profiles that may also be cardio-protective,


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

IGF-2R↑, 1,   miR-106b↓, 1,   PGI2↓, 1,  

Cell Death(tgid=5) ⓘ

p‑Akt↓, 1,   Apoptosis↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PTEN↑, 1,  

Migration(tgid=13) ⓘ

Ki-67↓, 1,   miR-19b↓, 1,   TumCP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   Inflam↓, 1,   PGE2↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   Dose↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   chemoPv↑, 1,   toxicity↝, 1,  
Total Targets: 18

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PGI2, Prostacyclin / Prostaglandin I2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1627  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page